Evelo Biosciences (Evelo Biosciences) Days Payable : 0.00 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Evelo Biosciences Days Payable?

Evelo Biosciences's average Accounts Payable for the three months ended in Sep. 2023 was $2.15 Mil. Evelo Biosciences's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for Evelo Biosciences's Days Payable or its related term are showing as below:

EVLO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 152.29
* Ranked among companies with meaningful Days Payable only.

Evelo Biosciences's Days Payable stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00). stayed the same

Evelo Biosciences Days Payable Historical Data

The historical data trend for Evelo Biosciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evelo Biosciences Days Payable Chart

Evelo Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

Evelo Biosciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Evelo Biosciences's Days Payable

For the Biotechnology subindustry, Evelo Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evelo Biosciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evelo Biosciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Evelo Biosciences's Days Payable falls into.

Evelo Biosciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Evelo Biosciences's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (1.601	+	1.764)	/	2 )	/	0	*	365
=	1.6825					/	0	*	365
=	N/A

Evelo Biosciences's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

	Days Payable (Q: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (3.765	+	0.526)	/	2 )	/	0	*	365 / 4
=	2.1455					/	0	*	365 / 4
=	N/A

Evelo Biosciences Days Payable Related Terms

Thank you for viewing the detailed overview of Evelo Biosciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Evelo Biosciences (Evelo Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evelo Biosciences Inc (OTCPK:EVLO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

620 Memorial Drive, 5th Floor, Cambridge, MA, USA, 02139

Website

https://www.evelobio.com

Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.

Executives

Simba Gill	director, officer: President & CEO	515 GALVESTON DR, REDWOOD CITY CA 94063
Mark Bodmer	officer: See Remarks	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Marella Thorell	officer: Chief Financial Officer	1226 CHARTER LANE, AMBLER PA 19002
Duncan Mchale	officer: Chief Medical Officer	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Alexander C Reynolds	director	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Horizon Technology Finance Corp	10 percent owner	312 FARMINGTON AVENUE, FARMINGTON CT 06032
Jeffrey R. Moore	director	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Robert L. Rosiello	director	400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Stephen J Carriere	officer: Principal Accounting Officer
David R Epstein	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Lord Ara Darzi	director	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Tonya Williams	director	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139